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Abstract  
Background 
Sickle cell disease (SCD) is the commonest severe monogenic disorder of humans. In Africa, 50-
90% of children born with SCD die before they reach their fifth birthday. 
  
Methods  
We conducted a prospective study among a cohort of children on the coast of Kenya. Members 
were typed for SCD and followed for survival status and disease-specific admission to Kilifi 
County Hospital by passive surveillance. Children with SCD were offered confirmatory testing 
and care at a dedicated outpatient clinic.  
 
Findings 
Of 15,702 infants recruited to the study one-hundred-and-twenty-eight (0.8%) had SCD of whom 
70 (54.7%) enrolled at the clinic. Mortality was higher in children with SCD than in those without 
[58 versus 2.4/1000PYO; adjusted Incidence Rate Ratio (aIRR) 23.1, 95% CI 15.1-35.3]. Among 
SCD children, mortality was lower in those who enrolled at the clinic (aIRR 0.26; 0.11-0.62) and 
in those with higher levels of Haemoglobin F (HbF) (aIRR 0.40; 0.17-0.94). The incidence of 
admission to hospital was also higher in children with than without SCD (210 versus 43/1000PYO; 
aIRR 4.80; 3.84-6.15). The most common reason for admission among those with SCD was severe 
anaemia (a haemoglobin concentration of <50g/L) [incidence 48 (32-71)/1000PYO]. Rates were 
lower in those with higher levels of HbF (aIRR 0.43; 0.2-0.7) or with co-existing homozygous -
thalassaemia (aIRR 0.07; 0.01-0.83).  
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Interpretation 
While both morbidity and mortality remain high in young children with SCD in this Kenyan 
cohort, both are reduced by early diagnosis and supportive care. The emphasis now must move 
towards early detection and on the prevention of long-term complications.  
 
Funding 
The study was funded by Senior Research Fellowships awarded to TNW (091758 and 202800) 
and JAGS (098532), and by core support to the KEMRI–Wellcome Trust Research Programme in 
Kilifi, Kenya (203077), all awarded by the Wellcome Trust. 
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Introduction  
Sickle cell disease (SCD) is a major, but widely neglected public health problem in low-income 
countries.1 Recent estimates suggest that in many parts of Africa, approximately 1% of all births 
are affected by SCD2 and that the condition is responsible for 6 to 15% of all deaths in children 
<5yrs old.3  HbS has been selected to high frequencies in many tropical populations through a 
survival advantage in carriers (with sickle cell trait: HbAS), against death from Plasmodium 
falciparum malaria.4 However, positive selection for carriers has been balanced by negative 
selection for homozygotes with sickle cell disease (HbSS), which in Africa is associated with 
under-5 mortality of 50-90%.5  
 
Globally, approximately three-quarters of all those affected with SCD live in sub-Saharan Africa, 
where an estimated 240,000 HbSS babies are born every year.2 Nevertheless, in contrast to high-
income regions, few studies have documented the natural history of SCD in Africa.6 This is 
important, because it may differ for reasons that include high rates of undernutrition, the heavy 
burden of malaria and other infectious diseases, and more limited medical care.2,7 Here, we 
describe the epidemiology of SCD in early life through a cohort study conducted on the coast of 
Kenya.  
 
Methods 
Study participants 
The study was conducted in members of the Kilifi Genetic Birth Cohort Study (KGBCS) on the 
Indian Ocean coast of Kenya.8 Recruitment to the study was facilitated through the Kilifi Health 
and Demographic Surveillance System (KHDSS), which covers a resident population of 260,000 
people and which has been described in detail previously.9 Rolling recruitment to the KGBCS was 
undertaken during the period 1st January 2006 to 30th April 2011. All children who were born 
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within the KHDSS area and who were 3-12 months old during the recruitment period were eligible 
with the exception of those who had already been recruited to other biomedical studies. The homes 
of eligible infants were visited (to a maximum of three attempts) by a team who sought consent 
from their parents, if at home. Capillary blood samples (200-500mcl) were collected into EDTA 
and tested for SCD at the laboratories of the KEMRI-Wellcome Trust Research Programme 
(KWTRP) in Kilifi. Test results, reported as SCD or no SCD, were fed back to parents as described 
in detail previously.10 Those testing positive were offered basic counselling about SCD, its mode 
of transmission and clinical consequences, confirmatory testing and a package of basic out-patient 
care at Kilifi County Hospital, the only provider of specialist services within the region. This 
included parental education regarding SCD, its mode of inheritance and potential consequences, 
and the provision of pneumococcal prophylaxis with penicillin V (250mg once daily until the age 
of 5 years), malaria prophylaxis with proguanil (3mg/kg/day), and folic acid supplementation (5mg 
once daily), all offered through 3-monthly clinic appointments.  Participants who enrolled at the 
clinic were also issued with emergency cards for fast-track access to the paediatric wards when 
sick. All infants received routine vaccinations including the Haemophilus influenzae type b (Hib) 
conjugate vaccine, which was introduced in Kenya in 2001. The 10-valent pneumococcal 
conjugate vaccine (PCV10) was introduced in Kenya in January 2011, accompanied by a catch-
up campaign in Kilifi County for children <5 years. As a result, most cohort members received 
this vaccine but at various ages after recruitment. Hydroxyurea therapy was not available at the 
time of the study. The study population has been described in detail previously;9 however, of 
particular relevance to the current study, levels of education within the area are among the lowest 
in Kenya, only 71% and 13% of 15-30 year olds having completed primary and secondary 
education respectively. Only 35% of the population live in semi-permanent or permanent housing 
of solid construction, while the majority follow a lifestyle of subsistence farming under conditions 
of poor soils and unreliable rainfall.    
 6 
 
Participant follow-up 
Study participants were followed passively for a range of specific outcomes until their fifth 
birthday. Their vital status (alive, dead or out-migrated) was recorded thrice-yearly through 
linkage to the population register of the KHDSS9 while disease-specific hospital admissions were 
recorded through linkage to an established surveillance platform on the paediatric wards of Kilifi 
County Hospital.9 Briefly, all children who are residents of the study area covered by the KHDSS 
are identified and linked in real-time to a computerized database at the time of hospital admission. 
All admitted children are assessed by trained clinicians who record data (including admission and 
discharge diagnoses) on a standard proforma.9 Routine laboratory tests are also conducted at 
admission, including full blood counts, malaria blood films, and blood cultures.11 For the purposes 
of this study, we used the WHO definition for severe anaemia: a haemoglobin concentration of 
<50g/L.12 For admissions among those with SCD, specific complications that were not captured 
routinely through the ward surveillance system such as painful crisis and hand-foot syndrome, 
were classified through retrospective examination of hospital notes. Because this assessment was 
conducted retrospectively, and no specific training was offered in advance to the numerous 
admitting clinicians who worked at the hospital during the study period, these data should be 
considered as indicative only. At the time of the study, Kilifi County Hospital was the only public 
hospital providing care for the population of Kilifi County and was the main admission facility for 
life-threatening illnesses in children.9 SCD remains widely stigmatised within the region,13 and at 
the time of the study no patient-support groups or community organizations were active in this 
area. 
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Laboratory procedures 
Recruitment blood samples were stored at 40C and tested for HbS within five days of collection 
using a Bio-Rad Variant™ Classic HPLC analyser (BioRad, Hercules, CA, USA). SCD was 
diagnosed if the major Hb peak was HbS and no HbA was present. Confirmatory PCR-based 
testing was undertaken in all such participants using genomic DNA extracted as previously 
described.8 All inconsistencies between the phenotyping and genotyping results were resolved 
through DNA sequencing.14 All participants were further genotyped for the common African 3.7kb 
α+thalassaemia deletion, as described previously.15 No other laboratory tests were conducted 
routinely on these recruitment samples. All blood tests collected through the paediatric ward 
surveillance platform were processed as previously described.9 Full blood counts were conducted 
on a range of automated counters supplied by Beckman Coulter (High Wycombe, UK); 
reticulocyte counts were not included as a routine. All assays were conducted at the laboratories 
of the KWTRP in Kilifi, Kenya. 
 
Statistical analysis 
All analyses were conducted using Stata v15.1 (Stata Corp, Timberlake, USA). Continuous data 
were compared using parametric or non-parametric tests as appropriate, while proportions were 
compared using the 2 test. We calculated the incidence of syndrome-specific admission to Kilifi 
County Hospital from the number of events and the person years of observation (PYO).8 PYOs for 
hospital admission and death were calculated based on follow up times from the date of birth and 
the date of recruitment respectively. Incidence rate ratios (IRRs) for death and for both overall and 
disease-specific admission to Kilifi County Hospital were derived using a generalised Poisson 
regression model, both with and without adjustment for age at recruitment, ethnic group and -
thalassaemia genotype. Survival time in the analysis was age while date of recruitment and date 
of birth were considered as entry to risk for death and admissions respectively. For the point of 
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exit from risk we took the earliest of death, outmigration or the 5th birthday. Because the analysis 
was conducted after the last child recruited was at least 5 years old, all cohort members were 
censored at one of these points. Results were represented visually using Kaplan Meier survival and 
Nelson-Aalen cumulative hazards graphs respectively. Children with SCD were sub-categorized 
based on their haemoglobin F (HbF) level at recruitment (above or below the median value for 
their age, categorised as 3-5, 6-8 and 9-11months), their SCD genotype (HbSS or HbS/-
thalassaemia), and whether or not they registered for management at the SCD outpatient clinic at 
Kilifi County Hospital within twelve months of recruitment to the study. P-values of <0.05 were 
considered significant.   
 
Ethics 
Written informed consent for inclusion in the KGBCS was obtained from the parents of all 
participants while ethics permission for the study was obtained from the Kenya Medical Research 
Institute/National Ethical Review Committee in Nairobi, Kenya and the Oxford Tropical Research 
Ethics Committee in the UK. 
 
Results 
Cohort characteristics 
The profile of cohort recruitment is summarised in Figure 1. In total, 52,537 children were born 
within the KHDSS area and were 3-12 months of age during the recruitment period. Of these 
infants, 15,737 (29.9%) were recruited successfully to the KGBCS at a median age of 6.6 
(interquartile range 5.1-8.7) months. The characteristics of recruited and non-recruited children 
with regard to a wide range of factors were broadly similar, although a significantly lower 
proportion of children were recruited from the urban area within the Kilifi township (Table S1). 
Of those recruited successfully, 35 were dropped from the current analysis because insufficient 
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blood was obtained for SCD testing leaving 15,702 contributing to the current study. In total, 
HPLC analysis was consistent with SCD in 128/15,702 (0.8%) cohort members.  Confirmatory 
testing by PCR showed that 118/128 (92%) were rs334 homozygotes (HbSS) while 10/128 (8%) 
were rs334 heterozygotes. The latter were further investigated by sequencing which showed that 
all were compound heterozygotes for HbS plus one of three different 0thalassaemia mutations 
[CD22 (GAA➝TAA), initiation codon (ATG➝ACG) and IVS1-3ʹ end del 25bp]), as described 
in detail elsewhere.14 Typing for -thalassaemia was successful in 15,451/15,702 (98.4%) 
participants of whom 7,503 (48.5%) and 2,614 (16.9%) were heterozygotes and homozygotes 
respectively. Among children with SCD, 127 (99%) were typed successfully for -thalassaemia 
of whom 51 (41%) were heterozygotes and 18 (14%) homozygotes. Although the parents of all 
infants diagnosed with SCD were informed and invited to enrol their children at the SCD clinic 
only 70/128 (54%) accepted this offer within 12 months of recruitment. 
 
Mortality by sickle cell disease status 
Overall, a total of 174 participants died before aged 5-years during a total of 61,446PYO - a crude 
mortality rate of 2.8/1000PYO (95% CI 2.4-3.2). The Kaplan Meier survival curves for SCD and 
non-SCD participants are shown in Figure 2A. There were 26 deaths in 445PYO and 148 deaths 
in 61,001PYO among children with and without SCD respectively, resulting in mortality rates 
(95% CI) of 58 (40-86) and 2.4 (2.0-2.8)/1000PYO, respectively [adjusted IRR (aIRR) 23.1 (15.1-
35.3)]. Mortality in those with SCD was significantly lower among those with a recruitment HbF 
level above versus below the age-standardized median and among those who enrolled at the SCD 
clinic versus those who did not (Table 1). Trends were also seen towards a lower mortality in 
homozygotes for -thalassaemia and in participants with HbS/0thalassaemia (Table 1 and Figures 
S1-S4).  
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Hospital admission by sickle cell disease category 
A total of 3,146 admissions were observed in 15,702 cohort members during 70,478PYO - an 
overall incidence of 45 (95% CI 43-46)/1000PYO. Fifty eight percent of the admissions (N=1830) 
were in unique participants while the rest (N=1316) occurred as multiple admissions within single 
individuals (Table S2). The characteristics of hospital admitted participants, stratified by SCD 
status, are summarized in Table 2. In comparison to those without, participants with SCD had lower 
haemoglobins and platelet counts and higher white blood cell counts. Only one positive blood film 
was recorded among admitted SCD participants, in which the parasite density was significantly 
lower than that seen in non-SCD participants during the same observation period (Table 2). The 
relative risk of admission to hospital among SCD and non-SCD children varied with age, as shown 
in Figures 2B and 2C. The aIRR was 0.18 (0.02-1.2) among children <3 months of age but rose 
thereafter to reach 4.7 (3.0-7.4) in children 6-12 months of age. The incidence of admission to 
hospital with a range of specific diagnoses is summarized, stratified by SCD status, in Table 3 while 
IRRs in comparison to non-SCD children are summarized in Table 4. Overall the incidence of 
admission was almost five-fold higher in those with SCD than in those without. A higher proportion 
of SCD (25/109; 22.9%) than non-SCD (83/3037; 2.7%) participants were severely anaemic at 
presentation (p<0.0001) or received a blood transfusion during their admission [20/109 (18.3%) 
versus 101/3037 (3.3%), respectively] (Table 3). As a result, children with SCD accounted for 
16.5% of transfusions received by cohort members as a whole during the period of observation. 
The incidence rates (per 1000PYO) for admission with specific SCD-associated syndromes were: 
painful crises 58 episodes (40-83); hand-foot syndrome 12 (5-26), strokes 4 (1-15) and 
osteomyelitis 2 (0-14).  
 
Finally, among cohort members with SCD, the risk of admission was significantly associated with 
a number of factors. Overall, it was lower in both those with a recruitment HbF level above the 
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median (IRR 0.43; 0.24-0.78; p=0.005) and those who were homozygous for -thalassaemia (IRR 
0.07; 0.01-0.83; p=0.035). Conversely, admission rates were higher in those who enrolled at the 
SCD clinic than in those who did not (IRR 2.02; 1.10-3.70; p=0.022) while no differences were 
seen by SCD genotype (HbSS versus HbS/-thalassaemia) (Table 4).  
 
Discussion 
Here we have described the rates of under-five mortality and disease-specific hospital admission 
among a cohort of children living on the coast of Kenya with a particular emphasis on SCD. 
Overall, SCD affected 0.8% of cohort members in whom the rates of admission to hospital and 
death were almost 5-fold and more than 20-fold higher, respectively, than in those without SCD. 
Furthermore, we found that survival was significantly higher among SCD children who registered 
for specialist outpatient care. Our study provides a rare description of the clinical epidemiology of 
SCD from Africa, where the majority of affected persons are born.  
 
Most previous studies investigating the clinical course of SCD in Africa have been based on 
cohorts of older subjects,16 patients attending outpatient clinics17,18 or on those admitted to 
hospital.19-21 As such, most have involved a selected and potentially unrepresentative sub-group 
who have survived to the point of diagnosis. Although mortality data have been reported from one 
previous birth cohort study, the number of SCD children included was low, and detailed data on 
disease-specific events were not reported.22 Finally, while several new-born screening projects 
have been conducted in recent years,23-26 none have reported on detailed outcomes. While the final 
number of children with SCD that were followed is a limitation of our study, it still provided 
sufficient power to make significant observations in a number of key areas and with reference to 
the above, to the best of our knowledge, our study provides the most comprehensive description 
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of the epidemiology of SCD in an unselected cohort of children that has been conducted in Africa 
to date.  
 
While overall mortality in participants with SCD was 58 (40-86)/1000PYO this varied according 
to a number of factors. Of particular note, it was more than halved among children who enrolled 
at the clinic compared to those who did not, in whom mortality was consistent with our earlier 
estimate of 50-90% among undiagnosed and untreated children from across Africa.5 Although this 
could reflect parental attitudes to modern health services, it also suggests that early diagnosis 
accompanied by the provision of parental education and basic clinical care can lead to substantial 
reductions in early mortality in Africa, just as they did in studies conducted in the United States 
more than 30 years ago.27 The fact that the latter would be readily affordable to governments in 
many parts of the continent28 argues for the implementation of such services more widely. Through 
a clinical trial we recently illustrated the morbidly and survival benefits that can come with the 
addition of carefully-monitored hydroxyurea therapy to this basic package of care.29 However, 
given the complex clinical oversight that normally accompanies the use of hydroxyurea, 
implementing therapy at scale will be a challenge that will either require substantial investments 
in equipment and personnel or further studies that confirm the safety of more pragmatic approaches 
to monitoring. 
 
In agreement with observations from studies conducted in high-income countries,30 survival was 
positively associated with HbF. Mortality was almost 3-fold lower in SCD participants whose 
base-line levels were above the median for their age at recruitment. Furthermore, consistent with 
previous studies,31 a trend was also seen towards improved survival in those with -thalassaemia.  
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Despite the fact that only 0.8% of the cohort had SCD, children with the condition accounted for 
3.5% of all admissions during the study period. Overall, the incidence of hospital admission in 
participants with SCD was 210/1000PYO. However, this varied with age, being below normal in 
the first 3 months of life before crossing over in older ages. This observation suggests that the 
youngest children with SCD might even be healthier than those without. Three mechanisms seem 
plausible, all of which relate to malaria. First, almost all of the mothers of SCD children will have 
been carriers of HbAS and will have been naturally protected against pregnancy associated 
malaria. Second, on the basis of previous studies, it appears that HbSS red cells are even more 
resistant to malaria than HbAS red cells and may therefore have provided a malaria-protective 
advantage during pregnancy.32 Finally, the rate of decline of HbF is significantly slower in children 
with SCD than those without,33 which could have led to further protection against P. falciparum 
malaria.34 All three of these mechanisms could potentially have resulted in the birth of stronger, 
healthier babies with a reduced susceptibility to a wide range of both infectious and non-infectious 
diseases.32  
 
Given that the study was conducted in a resource-poor region where the majority of children die 
outside of health facilities and where post-mortem examinations are not routinely available, we 
were not able to identify the causes of death in the vast majority of children. As a result, it was not 
possible to investigate the relationship between specific causes of death and individual exposures 
such as compliance with particular interventions. Furthermore, because the study was conducted 
in the context of routine clinical care, and detailed research follow up of children diagnosed with 
SCD was not part of the design, we do not have data on the level of compliance with routinely 
prescribed drugs. 
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The increased rate of admission observed among older children is likely to be conservative for 
several reasons. First, the costs associated with admission (including transport, hospital fees and 
missed employment opportunities) are a deterrent to many families.35 Second, although Kilifi 
County Hospital is the main provider of medical care within the study area, it is likely that some 
children will have sought care at other facilities both within and beyond the study borders. Finally, 
we will only have captured the most severe clinical events by passive surveillance. As a 
consequence, the full burden of SCD within our cohort may be considerably higher.    
 
As previously reported,36 following an era of unprecedented decline, malaria transmission was low 
within the study area during the study period and, as a result, few children were admitted with 
malaria overall. Nevertheless, our current study does not suggest an increased susceptibility to 
malaria among children with SCD, an observation consistent with previous reports.37 Declining 
malaria is probably the reason why the incidence rates for admission to hospital with severe 
anaemia were also substantially lower, both in children with and without SCD, than those seen in 
our earlier study conducted at the same hospital.21 Nevertheless, in the current study anaemia was 
still an important cause for admission in those with SCD, among whom 23% were severely 
anaemic. Eighty percent of this group received a transfusion meaning that, overall, children with 
SCD received 16.5% of all transfusions given to all cohort participants during the study period.  
Given the strong association between malaria and bacteraemia,38 the decline in malaria might also 
have contributed to the lower rates of bacteraemia in children with SCD compared to those seen 
in earlier studies conducted in the same area.8,21 However, the rollout of newer vaccines and the 
provision of penicillin prophylaxis may also have contributed. Whatever the cause, it seems likely 
that the falling rate of bacteraemia is a strong driver of improved survival. 
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In contrast to our findings for death, the incidence of admission to hospital among children enrolled 
at the SCD clinic was more than twice that of participants who were not.  It seems likely that this 
reflects the impact of education, through which children attending the clinic are encouraged to 
seek urgent treatment in the event of inter-current illnesses, and the fact that many admissions 
were also triggered by findings made at routine out-patient visits. Our study did not include the 
collection of detailed social or economic data that could provide additional explanations for 
variation in some of our outcomes, something that should be considered in future investigations.  
 
From the current study it is clear that a growing proportion of children with SCD on the coast of 
Kenya are now surviving, reaching medical attention, and requiring life-long care. In future, policy 
decisions regarding how best to diagnose and manage children with SCD and to prevent its 
complications, should be major priorities for health research in Africa. 
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Table 1. Deaths among children with sickle cell disease, stratified by a range of baseline factors. 
 
Exposure Deaths PYO Incidence$  IRR  95% CI P aIRR 95% CI* P 
          
SCD clinic enrolment          
No 18 172 104 1 n/a n/a 1 n/a n/a 
Yes 8 273 29 0.28  0.12-0.65 0.003 0.26 0.11-0.62 0.002 
 
HbF levels 
         
Below the median 18 213 85 1 n/a n/a 1 n/a n/a 
Above the median 8 232 34 0.40  0.17-0.92 0.032 0.40  0.17-0.94 0.036 

+thalassaemia  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal  13 186 70 1 n/a n/a 1 n/a n/a 
Heterozygous 12 183 66 0.94  0.43-2.07 0.89 1.10  0.46-2.25 0.80 
Homozygous 1 72 14 0.19  0.02-1.51 0.11 0.19  0.02-1.49 0.11 
 
-thalassaemia 
         
Without -thalassaemia 25 408 61 1 n/a n/a 1 n/a n/a 
With -thalassaemia 1 37 27 0.42  0.05-3.15 0.40 0.54  0.06-4.36 0.56 
$Incidence / 1000PYO; *IRRs adjusted for age at 
recruitmentthalassaemia genotype and ethnic group with the 
exception of the thalassaemia analysis where adjustment was for 
age at recruitment and ethnic group only. 
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Table 2. Clinical and laboratory characteristics of hospital-admitted patients, stratified by sickle 
cell disease status.  
 
 
 
 
P-values were estimated using the Student’s t-test or Mann-Whitney test as appropriate.  $Data denote values for the sub-set of 
children with positive malaria blood films. N/A - not applicable - only one SCD participant was admitted to hospital with a positive slide 
during the period of observation. IQR - interquartile range; WAZ - weight for age z-score; HAZ - height for age z-score; MCV - mean 
cell volume; WBC - white cell count; $ among those with positive blood films (geometric means); * only one positive blood film was 
seen among admission in children with SCD.  
 
 
Characteristic non-SCD SCD P 
All admissions (n, %) 3,037 (96.5) 109 (3.5) n/a 
Median age (IQR; months) 11.0 (3.2-22.6) 21.1 (12.5-32.7) 0.22 
Mean WAZ (95% CI) -1.6 (-1.6, -1.5) -1.8 (-2.0, -1.6) 0.27 
Mean HAZ (95% CI) -1.3 (1.4, -1.2) -1.1 (-1.3, -0.9) 0.13 
Mean haemoglobin (95% CI; g/L)  10.3 (10.2-10.4) 6.4 (6.0-6.9) <0.001 
Mean MCV (95% CI; fL) 73.7 (73.1-74.2) 78.0 (75.7-80.4) 0.003 
Median WBC (IQR; x109/mcl)  12.9 (9.5-17.5) 26.5 (19.4-32.6) <0.001 
Platelets (95% CI; x10⁶/L)  423 (415-431) 356 (318-393) 0.002 
P. falciparum parasites (per l whole blood)$ 60,293 (45,908-79,185) 26,196* <0.001 
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Table 3. The incidence of admission to hospital with a range of clinical conditions by sickle cell 
disease status.  
 
 non-SCD participants SCD participants    
 Events Incidence  Event
s 
Incidence aIRR 95% 
CI 
P 
Clinical 
syndromes 
              
All cause hospital 
admission 
3,037 43 109 210 4.8 
3.8-
6.1 
<0.00
01 
Neonatal 
conditions$ 
496 413 1 101 0.3 
0.0
3-
1.9 
0.18 
Malaria 241 3 1 2 0.5 
0.1-
3.8 
0.53 
Severe 
pneumonia 
1004 14 24 46 3.8 
2.5-
5.8 
<0.00
01 
Very severe 
pneumonia 
518 7 12 23 3.4 
1.9-
6.1 
<0.00
01 
Meningitis/enceph
alitis  
1062 15 15 28 2.1 
1.2-
3.6 
0.005 
Severe 
malnutrition 
260 4 6 12 3.6 
1.6-
8.1 
0.002 
Gastroenteritis 600 8 7 13 1.8 
0.9-
4.0 
0.09 
Jaundice 110 2 17 33 20.4 
11.
5-
36.
2 
<0.00
01 
Other 577 8 50 96 12.0 
8.5-
16.
1 
<0.00
01 
        
Laboratory 
features and 
outcome 
       
Bacteraemia^ 364 5 15 29 6.0 
3.5-
10.
4 
<0.00
01 
Malaria blood film 
positive 
270 4 1 2 0.5 
0.1-
3.5 
0.47 
Severe anaemia£ 83 1 25 48 39.1 
24.
5-
62.
5 
<0.00
01 
Transfused  101 1 20 38 27.0 
16.
3-
44.
8 
<0.00
01 
Hospital deaths 47 0.7 4 8 11.0 
3.9-
30.
9 
<0.00
01 
 
Footnote to Table 3. 
Clinical phenotypes were defined as follows: “neonatal conditions” - admission to hospital within 
the first 28 days of life; “malaria” - a fever in the presence of P. falciparum parasitaemia at any 
density in children <1 year old or at a density of >2500 parasites/l in older children; “severe 
malaria” - malaria in association with the specific complications of prostration, coma, respiratory 
distress or an admission Hb of <50g/L; “severe” and “very severe pneumonia” - defined as 
previously described;1 meningitis/encephalitis - the clinical detection of “neck stiffness”, 
prostration or coma (defined as a Blantyre Coma Score of <5), or a bulging fontanel; “severe 
malnutrition” - a mid-upper-arm circumference of ≤7.5cm in children <6 months or of ≤11.5 in 
children ≥6 months of age; “gastroenteritis” - diarrhoea (3 or more loose watery stools / day) 
with or without vomiting  (3 or more episodes / day); “jaundice” - the clinical recognition of 
jaundice by the admitting clinician. Some children contribute data to more than one row. ^Blood 
cultures among children with SCD were positive for Streptococcus pneumoniae (6; 40.0%), 
Salmonella spp (4; 26.6%), Enterobacter spp (2; 13.3%), Acinetobacter spp (2; 13.3%) and 
Staphylococcus aureus (1; 6.7%). £severe anaemia was defined as a haemoglobin 
concentration of <50g/L.  Some children contributed data to more than one syndrome. Incidence 
rates denote episodes/1000PYO. PYOs for non-SCD and SCD admissions were 69,959 and 
519 respectively. $ Data for the neonatal period reflect rates/1000 person months of observation 
(PMO). PMO were 15,568 and 128 for non-SCA and SCD respectively. aIRR = IRRs (and 95% 
CI) between participants with SCD in comparison to those without SCD adjusted for -
thalassaemia genotype and ethnic group.  
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Table 4. The incidence of admission to Kilifi County Hospital 
among children with sickle cell disease, stratified by a range 
of baseline factors. 
Exposure Admissions PYO Incidence IRR 
95% 
CI 
P aIRR 
95% 
CI 
P 
          
SCD clinic 
enrolment 
         
No 23 208 110   1    1   
Yes 86 311 276  2.16  1.19-
3.91 
0.011 2.02  1.10-
3.70 
0.022 
 
HbF levels 
         
Below the median  74 252 293  1  n/a 1  n/a 
Above the median 35 267 131  0.51  0.29-
0.89 
0.018 0.43  0.24-
0.78 
0.005 
          
+thalassaemia           
Normal 59 218 269  1  n/a 1  n/a 
Heterozygous 44 212 207  0.96  0.56-
1.65 
0.91 1.09 0.62-
1.89 
0.75 
Homozygous 6 83 72  0.26  0.07-
0.87 
0.030 0.07  0.01-
0.83 
0.035 
 
-thalassaemia 
         
With -
thalassaemia 
100 476 209  1   1   
Without -
thalassaemia 
9 43 206  0.90  0.33-
2.42 
0.83 1.08  0.38-
3.06 
0.87 
*Incidence rate ratios adjusted for thalassaemia genotype and ethnic group. 
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Figure 1. Cohort recruitment and follow up.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52,537 infants aged 3-12 months who were 
resident within the Kilifi Health and 
Demographic Surveillance system study area 
between January 2006 and April 2011 and 
eligible for consideration. 
7,192 infants not approached because 
they were ineligible through 
participation in other studies. 
45,345 infants approached for consent. 
Outmigrated from the study area 
(5,876) or died (174) before their 
recruitment visit.  
Recruitment attempted in 39,295 infants. 
15,130 infants not recruited because 
of absence from home at the time of 
the recruitment visits  
Consent sought from 24,165 parents. 
35 dropped because typing for sickle 
cell disease was unsuccessful 
 
128 (0.8%) participants with sickle 
cell disease.  
8,428 parents decline to consent to 
participation of their children in the 
study. 
15,737 successfully recruited to the study. 
15,702 children included in the study and 
followed for mortality and hospital admission 
events until their 5th birthday. 
15,574 (99.2%) participants without 
sickle cell disease.  
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Figure 2. Survival probability and cumulative hazard of admission.  
A 
 
B 
 
 
C 
 
A Kaplan Meier mortality plot and B Nelson-Aalen cumulative hazard plots for 
admission to hospital in children with and without SCD. C zoomed in Nelson-
Aalen plot for the first year of life. Bold lines represent non-SCD children and 
dashed lines SCD children. 
 
P<0.001 
P<0.001 
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Table S1. Characteristics of children eligible for recruitment to the cohort, stratified by 
whether or not they were successfully recruited. 
 
 
 
  
Characteristic Recruited Not recruited 
Follow-up for outcomes of interest   
Duration of follow up for deaths (PYO) 61,446 84,673 
Deaths (n) 174 231 
Deaths/1000 PYO (95% CI) 2.8 (2.4-3.2) 2.7 (2.3-3.1) 
Duration of follow up for admissions 
(PYO) 
70,478 115,683 
Admissions (n) 3,146 5,594 
Admissions/1000 PYO (95%CI) 45 (43-46) 48 (47-49) 
   
Gender   
Female 7,816 (49.7%) 18,251 (49.6%) 
Male 7,920 (50.3%) 18,560 (50.4%) 
   
Area of residence   
Banda ra Salama 882 (5.6%) 1,139 (3.1%) 
Chasimba 1,709 (10.9%) 2,119 (5.8%) 
Gede 708 (4.5%) 668 (1.8%) 
Jaribuni 346 (2.2%) 679 (1.8%) 
Junju 1,518 (9.6%) 4,548 (12.4%) 
Kauma 621 (3.9%) 1,273 (3.5%) 
Kilifi Township 944 (6.0%) 8,200 (22.3%) 
Matsangoni 1,295(8.2%) 1,686 (4.6%) 
Mtwapa 611 (3.9%) 1,777 (4.8%) 
Ngerenya 1,290 (8.2%) 1,825 (5.0%) 
Roka 1,326 (8.4%) 2,115 (5.7%) 
Sokoke 571 (3.6%) 1,206 (3.3%) 
Takaungu Mavueni 1,074 (6.8%) 4,180 (11.4%) 
Tezo 1,471 (9.3%) 3,718 (10.1%) 
Ziani 1,371 (8.7%) 1,667 (4.5%) 
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Table S2. The number of admissions among cohort members. 
  
The number of 
admissions per person 
non-SCD SCD 
N (%) 
0 13245 (85.04) 72 (56.25) 
1 1830 (11.75) 29 (22.66) 
2 364 (2.34) 12 (9.38) 
3 93 (0.60) 9 (7.03) 
4 31 (0.20) 3 (2.34) 
5 5 (0.03) 2 (1.56) 
6 3 (0.02) 0 (0) 
7 2 (0.01) 1 (0.78) 
9 1 (0.01) 0 (0) 
10 1 (0.01) 0 (0) 
Total 15575 128 
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Figure S1. Kaplan Meier survival curves for mortality among children with SCD, stratified by 
-thalassaemia genotype.  
 
 
 
Solid line: no-thalassaemia; dashed line: heterozygous -thalassaemia; dotted line: homozygous 
-thalassaemia. P-value determined by log-rank test for equality of survivor functions. 
 
  
P=0.28 
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Figure S2. Kaplan Meier survival curves for mortality among children with SCD, stratified by 
clinic attendance. 
 
 
 
 
 
Bold line: not enrolled; dashed line: enrolled. P-value determined by log-rank test for equality of 
survivor functions. 
  
P=0.011 
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Figure S3. Kaplan Meier survival curves for mortality among children with SCD, stratified by 
HbF levels at recruitment. 
 
 
 
 
 
Bold line: below the median; dashed line: above the median. P-value determined by log-rank test 
for equality of survivor functions. 
 
  
P=0.068 
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Figure S4. Kaplan Meier survival curves for mortality among children with SCD, stratified by 
SCD genotype.  
 
 
 
 
Bold line: HbSS; dashed line: HbS/-thalassaemia. P-value determined by log-rank test for 
equality of survivor functions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P=0.25 
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Figure S5. Nelson-Aalen cumulative hazard estimates for admission to hospital in children with 
SCD, stratified by -thalassaemia genotype.  
 
 
 
Cumulative hazard for admission by -thalassaemia genotype: Bold line – no-thalassaemia; 
Dash line – Heterozygous -thalassaemia; Dash-dot homozygous -thalassaemia. P-value 
determined by log-rank test for equality of survivor functions. 
 
 
  
P=0.001 
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Figure S6. Nelson-Aalen cumulative hazard estimates for admission to hospital in children with 
SCD, stratified by enrollment at the SCD clinic.  
 
 
 
Dashed line – enrolled at the SCD clinic within one year of recruitment; Bold line – not enrolled 
at the SCD clinic within one year of recruitment. P-value determined by log-rank test for equality 
of survivor functions. 
 
 
  
P<0.001 
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Figure S7. Nelson-Aalen cumulative hazard estimates for admission to hospital in children with 
SCD, stratified by HbF levels at the point of recruitment.  
 
 
 
 
Bold line – below the age-specific median value among children with SCD; Dash line – above the 
age-specific median value among children with SCD. P-value determined by log-rank test for 
equality of survivor functions. 
 
 
 
  
P<0.001 
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Figure S8. Nelson-Aalen cumulative hazard estimates for admission to hospital in children with 
SCD, stratified by SCD genotype.  
 
 
 
 
Bold line – SCD HbSS; Dashed line – HbS/-thalassaemia. P-value determined by log-rank test 
for equality of survivor functions. 
P=0.46 
